Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study

Video

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

CancerNetwork® sat down with Shaji Kumar, MD, from the Mayo Clinic at the 2021 European Hematology Association (EHA) Congress to talk about overall survival for patients with transplant-ineligible newly diagnosed multiple myeloma who were treated with daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone compared with lenalidomide and dexamethasone alone in the phase 3 MAIA trial (NCT02252172). At 5 years of follow-up, there was a significant reduction in the risk of death for patients taking both drug combinations.

Transcript:

This the first time that we have seen a difference in overall survival reported on this study. Obviously, with overall survival, we had to wait for much more mature data. With the current follow-up, what we see is that the 5-year overall survival [rates] for the daratumumab plus lenalidomide and dexamethasone was 66% compared with 53% for the lenalidomide and dexamethasone, which is, again, a significant improvement, or a 30% to 32% reduction in the risk of death when you use a 3-drug combination compared to the 2-drug combination.

Reference

Theirry F, Kumar S, Torben P, et al. Overall survival results with daratumumab, Lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at: 2021 European Hematology Association Annual Meeting; June 9-17, 2021; Virtual; Abstract LB1901. Accessed June 29, 2021. https://bit.ly/3hmf7l9

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
4 experts are featured in this series.
Related Content